李敬, 刘新泳, 展鹏. 人巨细胞病毒抑制剂研究进展J. 药学学报, 2020,55(4): 585-596. doi: 10.16438/j.0513-4870.2019-0729
引用本文: 李敬, 刘新泳, 展鹏. 人巨细胞病毒抑制剂研究进展J. 药学学报, 2020,55(4): 585-596. doi: 10.16438/j.0513-4870.2019-0729
LI Jing, LIU Xin-yong, ZHAN Peng. Advances in human cytomegalovirus inhibitorsJ. Acta Pharmaceutica Sinica, 2020,55(4): 585-596. doi: 10.16438/j.0513-4870.2019-0729
Citation: LI Jing, LIU Xin-yong, ZHAN Peng. Advances in human cytomegalovirus inhibitorsJ. Acta Pharmaceutica Sinica, 2020,55(4): 585-596. doi: 10.16438/j.0513-4870.2019-0729

人巨细胞病毒抑制剂研究进展

Advances in human cytomegalovirus inhibitors

  • 摘要: 目前的抗人巨细胞病毒(human cytomegalovirus,HCMV)感染药物存在活性中等、生物利用度差等问题,迫使人们不断研发新的抗HCMV药物。随着HCMV的致病机制和生物学特征的不断研究以及新的药物设计策略的快速发展,新一代抗HCMV感染的靶点和药物陆续被发现。本综述精选近几年最具代表性的研究实例,从药物化学角度总结了抗HCMV药物的新靶标及其研究进展。

     

    Abstract: At present, the anti-HCMV (human cytomegalovirus) drugs have some problems, such as moderate activity, poor bioavailability, which urge people to develop new anti-HCMV drugs. With the continuous study on the pathogenesis and biological characteristics of HCMV and the rapid development of new drug design strategies, new generation of anti-HCMV targets and drugs have been identified. This review selects the most representative research examples in recent years, and summarizes the new targets and research progress of anti-HCMV drugs from the perspective of medicinal chemistry.

     

/

返回文章
返回